Report overview
Human respiratory syncytial virus (HRSV) is a syncytial virus that causes respiratory tract infections. It is a major cause of lower respiratory tract infections and hospital visits during infancy and childhood. A prophylactic medication, palivizumab, can be employed to prevent HRSV in preterm (under 35 weeks gestation) infants, infants with certain congenital heart defects (CHD) or bronchopulmonary dysplasia (BPD), and infants with congenital malformations of the airway. Treatment is limited to supportive care, including oxygen therapy and more advanced breathing support with CPAP or nasal high flow oxygen.
This report aims to provide a comprehensive presentation of the global market for Human Respiratory Syncytial Virus Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Respiratory Syncytial Virus Drugs. This report contains market size and forecasts of Human Respiratory Syncytial Virus Drugs in global, including the following market information:
Global Human Respiratory Syncytial Virus Drugs Market Revenue, 2018-2023, 2024-2032, ($ millions)
Global Human Respiratory Syncytial Virus Drugs Market Sales, 2018-2023, 2024-2032, (K Units)
Global top five Human Respiratory Syncytial Virus Drugs companies in 2022 (%)
The global Human Respiratory Syncytial Virus Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
One trend in the market is emergence of new entrants likely to change market dynamics. The growing demand for novel products for the treatment of RSV has fueled the emergence of new entrants that are likely to change the market dynamics during the forecast period.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Human Respiratory Syncytial Virus Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Human Respiratory Syncytial Virus Drugs Market, by Type, 2018-2023, 2024-2032 ($ Millions) & (K Units)
Global Human Respiratory Syncytial Virus Drugs Market Segment Percentages, by Type, 2022 (%)
Approved Drugs
Off-Label Drugs
Global Human Respiratory Syncytial Virus Drugs Market, by Application, 2018-2023, 2024-2032 ($ Millions) & (K Units)
Global Human Respiratory Syncytial Virus Drugs Market Segment Percentages, by Application, 2022 (%)
Clinical Diagnostic
Laboratories Physicians' Office
Laboratories Hospitals
Global Human Respiratory Syncytial Virus Drugs Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions) & (K Units)
Global Human Respiratory Syncytial Virus Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Human Respiratory Syncytial Virus Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Human Respiratory Syncytial Virus Drugs revenues share in global market, 2022 (%)
Key companies Human Respiratory Syncytial Virus Drugs sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Human Respiratory Syncytial Virus Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
AstraZeneca
AbbVie
GSK
Teva Pharmaceutical
Outline of Major Chapters:
Chapter 1: Introduces the definition of Human Respiratory Syncytial Virus Drugs, market overview.
Chapter 2: Global Human Respiratory Syncytial Virus Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Human Respiratory Syncytial Virus Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Human Respiratory Syncytial Virus Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Human Respiratory Syncytial Virus Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
